RBS Downgrades Crucell N.V. (CRXL) to Hold
More News related to CRXL
- TapImmune (TPIV) In License Agreement with Crucell (CRXL)
- UBS Upgrades Crucell NV (CRXL) to Buy
- Crucell NV (CRXL) Posts Q3 EPS of €$0.15, In-Line with Street; Reiterates Guidance
- Calmune and Crucell Enter Exclusive Research Collaboration
- Crucell Announces Third Quarter 2009 Results
RBS downgrades Crucell N.V. (Nasdaq: CRXL) from Buy to Hold.
Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
